Cognition Therapeutics (NASDAQ: CGTX) reported a net loss of $23.5 million for the year ended December 31, 2025, a 31% improvement from the $34.0 million loss recorded in 2024. Earnings per share were $(0.32), up from $(0.86) a year earlier, reflecting tighter cost control and a more efficient operating profile.
Cash, cash equivalents, and restricted cash totaled $37.0 million at year‑end, while obligated National Institute of Aging grant funds stood at $35.7 million. Management indicated that the combined cash and grant balance should support operations and capital expenditures through the second quarter of 2027, extending the company’s runway despite the absence of product revenue.
R&D expenses fell as the company completed the SHINE and SHIMMER trials, while G&A costs decreased primarily due to a reduction in stock‑based compensation. These expense reductions contributed directly to the narrowed net loss and improved earnings per share.
The company also highlighted key clinical milestones: enrollment for the 545‑patient START trial in early Alzheimer’s disease was completed in December 2025, and a meeting with the FDA’s Division of Psychiatry is scheduled for 2026 to discuss the registrational pathway for its dementia with Lewy bodies psychosis program. These developments underscore Cognition’s focus on advancing zervimesine toward regulatory approval while managing a tight capital base.
Analysts had a consensus estimate of –$0.085 per share for Q4 2025; Cognition’s actual EPS of –$0.32 beat that estimate by $0.065, a margin that reflects disciplined cost management and the absence of one‑time charges. The beat signals confidence in the company’s financial discipline amid a challenging clinical‑stage environment.
Market reaction was mixed, with some investors cautious due to the long timelines for clinical data, while others welcomed the extended cash runway and the company’s progress on its lead candidate. The overall sentiment reflects a balance between the positive financial footing and the inherent uncertainties of drug development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.